The Tolmar deal with $35M upfront and up to $161.5M milestones provides cash runway through 2026; paired with ReSTART data catalyst (late 2026), REGAIN GBM data, and IMPACT pancreatic enrollment completion (Q3 2026), the stock's valuation is now tied to pipeline execution. Monitor for early ReSTART topline and any additional data at medical conferences. The warrants liability remeasurement could drive GAAP earnings volatility but is non-cash.
Price Chart
Executive Summary
Alpha Tau reported Q2 2026 EPS of -$0.26, a 84.6% miss versus consensus of -$0.14, with net loss widening to $68.8M for H1 2026 driven by $41.4M in financial expenses from warrant remeasurement. The filing highlights transformative clinical progress: 100% ORR in head and neck cancer with pembrolizumab, a strategic Tolmar partnership for prostate cancer including a $20M equity investment at a 25% premium, and completion of enrollment in the pivotal ReSTART cSCC trial. The strong clinical momentum and Tolmar deal are expected to overshadow the earnings miss, given the company's pre-revenue stage and focus on pipeline catalysts.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.26 missed consensus of -$0.14 by 84.6%; net loss for H1 2026 was $68.8M vs $18.8M in H1 2025
- Cash and equivalents + short-term deposits = $104.8M as of June 30, 2026, up from $76.9M at year-end 2025
- Tolmar collaboration: $20M equity investment at $11.99/share (25% premium), $15M for U.S. manufacturing, up to $161.5M milestones, supply at 60% of net sales
- Pivotal ReSTART cSCC trial completed enrollment at 88 patients; top-line data expected late 2026/early 2027
- Interim REGAIN glioblastoma data: 100% local control, 67% CR; FDA cleared final 7 enrollment slots and added 2 sites
- Head and neck cancer: 100% ORR with pembro, 18.2mo median OS vs 12.3mo historical benchmark
- H1 2026 R&D expenses $20.9M vs $14.2M; warrants liability remeasured to $47.5M due to share price increase
Financial Impact
Earnings miss of 84.6% overshadowed by clinical pipeline; $20M equity investment at premium is material positive. Net loss of $68.8M includes $41.4M non-cash charge from warrant remeasurement — core operating loss of $27.1M
Risk Factors
- Clinical trial risk: ReSTART primary endpoint failure would be a severe setback for PMA path
- Execution risk on Tolmar collaboration manufacturing expansion and regulatory milestones
- Warrant liability remeasurement may continue to produce large non-cash GAAP losses
- Pre-revenue; cash burn at $27.1M operating loss in H1 implies ~2-year runway, may need additional financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342184 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 6-K | $14.11 $15.19 | ▲ +7.65% | ▲ +7.84% | $14.77 (+4.68%) |
Aug 10, 2026 7w ago | 6-K | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | Press Release | $14.27 $14.27 | · 0.00% | ▲ +1.06% | $14.77 (+3.50%) |
Aug 10, 2026 7w ago | 6-K | $13.60 $14.84 | ▲ +9.12% | ▲ +10.03% | $14.77 (+8.60%) |
Jul 21, 2026 10w ago | 6-K | $13.32 $14.26 | ▲ +7.06% | ▲ +4.50% | $14.77 (+10.89%) |
Jul 15, 2026 11w ago | 6-K | $12.46 $13.87 | ▲ +11.32% | ▲ +8.97% | $14.77 (+18.54%) |
Jun 23, 2026 14w ago | 6-K | $10.05 $13.01 | ▲ +29.45% | ▲ +27.52% | $14.77 (+46.97%) |
Jun 3, 2026 17w ago | Press Release | $10.58 $13.23 | ▲ +25.05% | ▲ +26.05% | $14.77 (+39.60%) |
May 11, 2026 20w ago | Press Release | $10.34 $9.19 | ▼ −11.12% | ▼ −10.82% | $14.77 (+42.84%) |
May 8, 2026 21w ago | Press Release | $8.51 $9.35 | ▲ +9.87% | ▲ +9.85% | $14.77 (+73.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access